# Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)

> **NCT01362426** · — · COMPLETED · sponsor: **Janssen-Cilag Pty Ltd** · enrollment: 127 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** paliperidone palmitate

## Key facts

- **NCT ID:** NCT01362426
- **Lead sponsor:** Janssen-Cilag Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2016-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01362426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01362426, "Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01362426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*